MDXG
Price
$6.51
Change
-$0.21 (-3.12%)
Updated
Jul 18, 02:04 PM (EDT)
Capitalization
992.56M
12 days until earnings call
VCEL
Price
$35.31
Change
-$0.95 (-2.62%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
1.83B
12 days until earnings call
Interact to see
Advertisement

MDXG vs VCEL

Header iconMDXG vs VCEL Comparison
Open Charts MDXG vs VCELBanner chart's image
MiMedx Group
Price$6.51
Change-$0.21 (-3.12%)
Volume$100
Capitalization992.56M
Vericel
Price$35.31
Change-$0.95 (-2.62%)
Volume$10.83K
Capitalization1.83B
MDXG vs VCEL Comparison Chart in %
Loading...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDXG vs. VCEL commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDXG is a Hold and VCEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (MDXG: $6.72 vs. VCEL: $36.26)
Brand notoriety: MDXG and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDXG: 147% vs. VCEL: 126%
Market capitalization -- MDXG: $992.56M vs. VCEL: $1.83B
MDXG [@Biotechnology] is valued at $992.56M. VCEL’s [@Biotechnology] market capitalization is $1.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDXG’s FA Score shows that 1 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • MDXG’s FA Score: 1 green, 4 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, MDXG is a better buy in the long-term than VCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDXG’s TA Score shows that 5 TA indicator(s) are bullish while VCEL’s TA Score has 4 bullish TA indicator(s).

  • MDXG’s TA Score: 5 bullish, 5 bearish.
  • VCEL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDXG is a better buy in the short-term than VCEL.

Price Growth

MDXG (@Biotechnology) experienced а -0.88% price change this week, while VCEL (@Biotechnology) price change was -12.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.34%. For the same industry, the average monthly price growth was +13.98%, and the average quarterly price growth was +35.38%.

Reported Earning Dates

MDXG is expected to report earnings on Oct 29, 2025.

VCEL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+3.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCEL($1.83B) has a higher market cap than MDXG($993M). VCEL has higher P/E ratio than MDXG: VCEL (725.20) vs MDXG (24.89). MDXG YTD gains are higher at: -30.146 vs. VCEL (-33.965). MDXG has higher annual earnings (EBITDA): 62.1M vs. VCEL (10.6M). VCEL has more cash in the bank: 113M vs. MDXG (106M). MDXG has less debt than VCEL: MDXG (18.7M) vs VCEL (99M). MDXG has higher revenues than VCEL: MDXG (352M) vs VCEL (239M).
MDXGVCELMDXG / VCEL
Capitalization993M1.83B54%
EBITDA62.1M10.6M586%
Gain YTD-30.146-33.96589%
P/E Ratio24.89725.203%
Revenue352M239M147%
Total Cash106M113M94%
Total Debt18.7M99M19%
FUNDAMENTALS RATINGS
MDXG vs VCEL: Fundamental Ratings
MDXG
VCEL
OUTLOOK RATING
1..100
2068
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
8866
SMR RATING
1..100
4188
PRICE GROWTH RATING
1..100
5987
P/E GROWTH RATING
1..100
10100
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDXG's Valuation (66) in the Biotechnology industry is in the same range as VCEL (96) in the Medical Specialties industry. This means that MDXG’s stock grew similarly to VCEL’s over the last 12 months.

VCEL's Profit vs Risk Rating (66) in the Medical Specialties industry is in the same range as MDXG (88) in the Biotechnology industry. This means that VCEL’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for VCEL (88) in the Medical Specialties industry. This means that MDXG’s stock grew somewhat faster than VCEL’s over the last 12 months.

MDXG's Price Growth Rating (59) in the Biotechnology industry is in the same range as VCEL (87) in the Medical Specialties industry. This means that MDXG’s stock grew similarly to VCEL’s over the last 12 months.

MDXG's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for VCEL (100) in the Medical Specialties industry. This means that MDXG’s stock grew significantly faster than VCEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDXGVCEL
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
80%
Bearish Trend 4 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVCSX13.42N/A
N/A
Voya Small Company Port I
PPNMX10.70N/A
N/A
Principal SmallCap Growth I R3
RTLAX88.11N/A
N/A
Russell Inv Tax-Managed US Large Cap A
CGJAX70.54N/A
N/A
Calvert US Large Cap Growth Rspnb Idx A
CONWX18.38N/A
N/A
Concorde Wealth Management

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
+0.15%
AXON - MDXG
47%
Loosely correlated
+0.42%
VCYT - MDXG
42%
Loosely correlated
-3.77%
ARRY - MDXG
39%
Loosely correlated
-2.13%
RAPT - MDXG
38%
Loosely correlated
-2.76%
INM - MDXG
38%
Loosely correlated
+0.57%
More